<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051739</url>
  </required_header>
  <id_info>
    <org_study_id>C7098-R</org_study_id>
    <nct_id>NCT01051739</nct_id>
  </id_info>
  <brief_title>Variability in Perimetry Study</brief_title>
  <acronym>VIPII</acronym>
  <official_title>Improved Assessment of Visual Field Change</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improved Assessment of Visual Field Change is a trial aimed at investigating mechanisms of
      visual field testing variability. The investigators have found using larger stimulus size
      substantially lowers short-term variability. In this study, the investigators will determine
      if larger stimuli detect visual field change at an earlier time. The investigators are also
      developing a statistical model that accounts for correlations of neighboring test locations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disease of the optic nerve, including glaucoma, is the leading cause of blindness in the
      United States. Treatment decisions for optic nerve diseases are based largely on the changes
      in visual function that occur mostly as a consequence of disease progression. Unfortunately,
      the decision as to whether change of visual function has occurred is often difficult because
      of the high retest variability of conventional visual field testing (perimetry). This
      variability is so high that with moderate visual loss, a minimum of six tests are often
      needed in patients with optic nerve damage to reliably distinguish visual field deterioration
      from random variation. The preliminary data show that a substantial portion of the
      variability of perimetry lies in the type of stimulus used and the testing strategy applied.

      OBJECTIVES: The investigators propose to test the hypothesis that a large portion of total
      perimetric variability in patients with visual loss is due to a poor signal-to-noise ratio
      associated with using a small fixed-size stimulus.

      RESEARCH PLAN AND METHODS: To test this hypothesis, the investigators are examining patients
      with optic nerve diseases with conventional automated perimetry (size III) and tests having
      large-sized and scaled stimuli (size V, size VI (custom perimeter) and luminance size
      threshold perimetry - a test where threshold is found by changing stimulus size rather than
      stimulus intensity). Over four years the investigators will test 100 patients with and
      glaucoma and 60 normals each eight times. In addition, the investigators are retesting 50
      subjects once a week for 5 weeks. The investigators are also studying the associated
      structural-functional correlations using OCT and developing a statistical model that accounts
      for correlations of neighboring test locations.

      Perimetric variability and the reliable identification of visual field change is the single
      most difficult problem in visual testing today. The investigators anticipate identifying a
      method that allows efficient and accurate determination of visual field change.
      Identification of a superior method would (1) reduce the number of examinations needed,
      thereby reducing the costs of medical care; (2) minimize misdiagnosis, unnecessary testing
      and even unnecessary surgery that results from mistakenly interpreting fluctuation of the
      visual field as progression or improvement; (3) allow earlier disease intervention and (4)
      reduce the costs of clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Progressing in Each Group Using Pointwise Linear Regression</measure>
    <time_frame>4 years</time_frame>
    <description>Perimetric method that most efficiently detects visual field change. secondary outcome: number of subjects progressing in each group using pointwise linear regression Linear regression was used to determine visual field worsening (progression) at each of 52 test locations. We required 3 or more worsening test locations at a p = 0.05 significance level for their to be significant progression.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">180</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>normal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comparison of four visual field testing strategies</intervention_name>
    <description>We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        glaucoma patient with 0 to -25 dB mean deviation and normal subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean deviation of -20 or better with 5-8 points (optimally 10 points) with a value of
             p= 0.05 or better on the total deviation plot

          -  Mild cataract with VA of 20/30 or better pinholed

          -  Refractive error of = to or less than 6 diopters with = or less than 3.50 diopters of
             cylinder

          -  Pupil diameter of 3 mm minimum

          -  Controlled hypertension, diabetes, migraine

          -  Pseudophakic/refractive surgery if no vision problems

          -  Trabeculectomy okay

        Exclusion Criteria:

          -  History of other ocular or neurologic disease or surgery

          -  History of stroke

          -  Systemic disease [lupus, graves, cancer (within the last 5 yrs), AIDS, other]

          -  History of amblyopia

          -  Unreliable patient

          -  Frequently misses appointments

          -  Tests poorly

          -  Ocular hypertension

          -  Retinal problems

          -  Diabetic retinopathy

          -  Neurological disease (IIH, ON, AION)

          -  Cancer not in remission for the last 5 years

          -  Vein or artery occlusions

          -  Macular degeneration

          -  Trauma with vision loss

          -  Ocular inflammation (pars planitis, iritis, temporal aeuritis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa City VA Health Care System, Iowa City, IA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iowa City VA Health Care System, Iowa City, IA</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246-2208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wall M, Doyle CK, Eden T, Zamba KD, Johnson CA. Size threshold perimetry performs as well as conventional automated perimetry with stimulus sizes III, V, and VI for glaucomatous loss. Invest Ophthalmol Vis Sci. 2013 Jun 7;54(6):3975-83. doi: 10.1167/iovs.12-11300.</citation>
    <PMID>23633660</PMID>
  </reference>
  <reference>
    <citation>Kummet CM, Zamba KD, Doyle CK, Johnson CA, Wall M. Refinement of pointwise linear regression criteria for determining glaucoma progression. Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6234-41. doi: 10.1167/iovs.13-11680.</citation>
    <PMID>23908183</PMID>
  </reference>
  <results_reference>
    <citation>Wall M, Doyle CK, Zamba KD, Artes P, Johnson CA. The repeatability of mean defect with size III and size V standard automated perimetry. Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1345-51. doi: 10.1167/iovs.12-10299.</citation>
    <PMID>23341012</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vision testing</keyword>
  <keyword>perimetry</keyword>
  <keyword>glaucoma</keyword>
  <keyword>test variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We completed recruitment in the first three years of the grant period at out Visual Field Laboratory at the University of Iowa</recruitment_details>
      <pre_assignment_details>see inclusion and exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>glaucoma patients</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>normal ocular healthy controls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>glaucoma with mean deviation from 0 to -25 dB</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>normal - healthy observers with no eye pathology other than refractive error less than 6 diopters of correction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                    <measurement group_id="B2" value="61" spread="9"/>
                    <measurement group_id="B3" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Progressing in Each Group Using Pointwise Linear Regression</title>
        <description>Perimetric method that most efficiently detects visual field change. secondary outcome: number of subjects progressing in each group using pointwise linear regression Linear regression was used to determine visual field worsening (progression) at each of 52 test locations. We required 3 or more worsening test locations at a p = 0.05 significance level for their to be significant progression.</description>
        <time_frame>4 years</time_frame>
        <population>Those that completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Glaucoma</title>
            <description>mean deviation 0 to -25 dB</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Age-matched healthy observers were tested at baseline and then every six months for 4 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Progressing in Each Group Using Pointwise Linear Regression</title>
          <description>Perimetric method that most efficiently detects visual field change. secondary outcome: number of subjects progressing in each group using pointwise linear regression Linear regression was used to determine visual field worsening (progression) at each of 52 test locations. We required 3 or more worsening test locations at a p = 0.05 significance level for their to be significant progression.</description>
          <population>Those that completed study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.21</p_value>
            <p_value_desc>The a priori threshold of statistical significance is p&lt;0.05</p_value_desc>
            <method>Kaplan Meyer survival curves</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>glaucoma
Comparison of four visual field testing strategies: We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>normal
Comparison of four visual field testing strategies: We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>not all subjects completed the study (dropouts).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Wall, M.D.</name_or_title>
      <organization>Iowa City Veterans Administration Medical Center</organization>
      <phone>319-3380581</phone>
      <email>michael-wall@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

